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Dear Editor,
Pisa Syndrome (PS) is clinically defined as a pronounced
lateral flexion of the trunk (at least 10), completely
alleviated by passive mobilization or on lying supine [1].
PS has been described in patients with Parkinson’s dis-
ease (PD) and, until now, few studies have pointed out
its possible relationship with either clinical evolution of
disease and medical treatment. Although pathophysiology
of PS still remains largely unexplained a dopaminergic
impairment seems to play a major role in its onset.
Accordingly, in some PD patients, PS may be triggered
by starting of dopamine blocking agents, or by changes
in dopaminergic medication (e.g., start of a new drug,
and dose increase or decrease of existing medication). In
addition, non-dopaminergic medications might also con-
tribute for developing PS such as neuroleptics, lithium
carbonate, valproic acid, antidepressants, anti-emetics,
and cholinesterase inhibitors [1].
Here we describe the case of a 73-year-old woman
with a 5-year PD history, who showed, during an out-
patient visit, a lateral flexion of the trunk on the left side
(10 on spine X-ray). This abnormal posture was not
present at a previous clinical examination performed
6 months before. At current visit, the patient had not
awareness of the abnormal posture that was made evi-
dent by the physicians. The patient’s past medical history
was unremarkable and laboratory tests were normal. The
patient denied assumption of neuroleptics, antiemetics, or
cholinesterase inhibitors in the past years. Current treat-
ment regimen was pramipexole (1.57 mg/day), levodopa
(200 mg/day), and rasagiline (1 mg/day). Neurological
examination showed a right hand rest tremor, a slight
ipsilateral cogwheeling rigidity and bradykinesia, and a
lateral flexion of the trunk to the left side (Fig. 1a). The
patient underwent conventional EMG recordings in the
paravertebral muscles at the thoracic-lumbar level T12-
L1 (longissimus thoracis muscle) [2]. Recordings, that
were performed with the patient in stance position and
during voluntary right and left lateral trunk flexion,
showed a pattern of a co-contraction of agonist and
antagonist muscles compatible with dystonia of paraspi-
nal muscles (Fig. 2). As PS may be related to dopami-
nergic therapy [3], and according to recent observations
that PS might be reversed after rasagiline withdrawal [4],
we hypothesized that the onset of PS in our patient could
be linked to the last modification in the antiparkinsonian
treatment, that occurred nearly 1 year before when ra-
sagiline was added in order to manage motor worsening
and wearing-off phenomena. Based on these consider-
ations, rasagiline was withdrawn and, within 4 weeks, an
improvement of posture was observed (Fig. 1b). An
EMG examination performed 4 weeks after rasagiline
withdrawal showed disappearance of the abnormal dys-
tonic pattern (Fig. 2).
This report may further support the pathogenetic role
of the dopaminergic therapy in the development of PS in
PD, and its potential reversibility by optimizing the
regimen of antiparkinsonian medications. It is notewor-
thy that, in our patient, the temporal interval between
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rasagiline supplementation and PS appearance is quite
longer than previously reported [4]. Indeed, the trunk
deviation was not observed at an outpatient visit performed
6-months after rasagiline introduction, being recognized
only 1-year after this therapeutic change. This might lead to
consider rasagiline as a possible iatrogenic factor favoring
the onset of PS also when patients are on a stable thera-
peutic regimen for a relatively long time period.
The mechanism by which rasagiline may precipitate PS
in PD patients remains to be elucidated. The clinical effect
of rasagiline mainly relies on the inhibition of the mono-
amine oxidase type B, leading to an increase in the dopa-
mine extracellular levels at the striatal synapses. It is to
note that although IMAO-B are widely prescribed in PD,
only four cases of PS induced by rasagiline have been
described in literature until now [4]. This suggests that the
drug alone is probably not sufficient to induce the
syndrome, but a combination of genetic and clinical PD
characteristics might be needed [4]. On this regard, it has
been suggested that PS may represent a complication of
advanced PD in patients showing marked asymmetry of
symptoms, and detectable hyperactivity of the paraverte-
bral muscles on the less affected side, as we observed in
our patient [5].
In conclusion, the case we describe supports a previous
observation that PS may be related to the rasagiline
treatment [4]. In particular, our observation suggests that
even in the absence of a close temporal relationship
between rasagiline introduction and PS onset, resolution
of PS may be observed after rasagiline withdrawal.
Finally we emphasize the importance to recognize the
initial manifestations of PS in PD, before it evolves into a
chronic variant with irreversible changes affecting mus-
cles and bone structures.
Fig. 1 The patient posture
before (a) and 1-month after
(b) rasagiline withdrawal. The
postural bending (10) observed
before rasagiline
discontinuation completely
remitted 1-month after
rasagiline withdrawal. Informed
consent was received from the
patient for publication of the
image
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Fig. 2 EMG recordings of the right (R) and left (L) paravertebral
muscles when patient in standing position, and during right and left
lateral flexion of the trunk, before and after rasagiline withdrawal.
Before rasagiline withdrawal: tonic and persistent bilateral EMG
activity of the paraspinal muscles, markedly predominant on the left
side, was recorded in the upright standing position. The EMG
hyperactivity of the paraspinal muscles on the left side persisted
during voluntary right lateral trunk flexion, when an increasing in the
activity of the right paraspinal muscles was observed. The pattern of a
co-contraction of agonist and antagonist muscles was compatible with
dystonia of paraspinal muscles. After rasagiline withdrawal: hyper-
activity of the left paravertebral muscles along with abnormal co-
activation of left and right paravertebral muscles during right lateral
flexion completely remitted 1-month after rasagiline treatment was
discontinued. No evidence of myopathic or neuropathic abnormalities
was observed
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